Earnings ·
Reports Q3 revenue of $1.025 billion, raises full-year guidance to $3.8B-$3.9B
BMRNBiomarin Pharmaceutical Inc
BioMarin reported third-quarter total revenues of $1.025 billion, a 32% increase year-over-year, marking the first time quarterly revenue has exceeded $1 billion. The growth was driven by the recent acquisition of Amicus Therapeutics and increased demand for metabolic condition therapies. GAAP net loss widened to $123 million from $31 million in the prior year period, primarily due to intangible asset amortization, interest expense, and acquired in-process research and development charges related to the Alesta Therapeutics acquisition. Non-GAAP income rose to $45 million. The company updated its full-year 2026 revenue guidance to a range of $3.8 billion to $3.9 billion and lowered non-GAAP diluted EPS guidance to $2.80-$3.10, citing order timing uncertainty and significant IPR&D charges. BioMarin is a rare disease biotechnology company focused on developing and commercializing innovative genetic therapies.